Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Boral trials concrete with aggregates recarbonated via carbon capture
Tilt Renewables opens major BESS project in Victoria
FieldComm Group announces unified device integration roadmap
WA announces legislation to drive industry investment
Livium and UoM partner on microwave technology for REE extraction